CLINICAL CHARACTERISTICS IN DIFFUSE LARGE B-CELL LYMPHOMA
Keywords:
DLBCL, GCB group, non GCB group, clinical characteristics, IHCAbstract
According to immunohistochemistry, we can divide diffuse large B-cell lymphomas (DLBCL) into 2 major groups - germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) lymphoma and 2 minor groups - double positive (DP) and triple negative subgroup (TN). The aim of this study was to analyze clinical characteristics, treatment response and mortality between different groups of diffuse large B-cell lymphoma according to Han’s algorithm.
We analyzed the medical records of patients who were diagnosed as de novo diffuse large B-cell lymphoma in a cohort during a 12-year period. All patients were treated with RCHOP therapy. Medical records were reviewed for clinical information including age, sex, lactate dehydrogenase (LDH) levels, clinical stages, performance status (PS), extra nodal site involvement (ESI), International Prognostic Index (IPI) and B symptoms. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded 4-μm tissue sections. The antibodies used were CD20, CD10, BCL6, and MUM1.
The results showed that patients in the germinal center B-cell-like group had better clinical characteristics, treatment response and mortality than the non-germinal center B-cell-like group. Triple negative and double positive subgroups showed different clinical characteristics compared to the same group of origin.
These factors would provide valuable insights in predicting aggressiveness, redirecting treatment selections, and therefore, benefit in the survival of patients with DLBCL
References
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117(19): 5019-5032. doi: 10.1182/blood-2011-01-293050.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107(1): 265-276. doi: 10.1182/blood-2005-06-2508.
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116(19): 3724-3734. doi: 10.1182/blood-2010-05-282632.
Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2011; 117(11): 2530-2540. doi: 10.1002/cncr.25765.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16(8): 2780-2795. doi: 10.1200/ JCO.1998.16.8.2780.
No authors listed. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89(11): 3909-3918. PMID: 9166827.
Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol 2004; 124(2): 151-159. doi: 10.1046/j.1365-2141.2003.04749.x.
Grosskreutz C, Troy K, Cuttner J. Primary splenic lymphoma: report of 10 cases using the REAL classification. Cancer Invest 2002; 20(5-6): 749-753. doi: 10.1081/cnv-120002492.
Paryani S, Hoppe RT, Burke JS, Sneed P, Dawley D, Cox RS, et al. Extralymphatic involvement in diffuse non-Hodgkin's lymphoma. J Clin Oncol 1983; 1(11): 682-688. doi: 10.1200/JCO.1983.1.11.682.
Burton GV, Atwater S, Borowitz MJ, Huang AT. Extranodal Head and Neck Lymphoma: Prognosis and Patterns of Recurrence. Arch Otolaryngol Head Neck Surg 1990; 116(1): 69-73. doi:10.1001/archotol.1990.01870010073021.
Rudders RA, Ross ME, DeLellis RA. Primary extranodal lymphoma: response to treatment and factors influencing prognosis. Cancer 1978; 42(2): 406-416. doi: 10.1002/1097-0142(197808)42:2<406::aid-cncr2820420205>3.0.co;2-h.
Bunn PA Jr, Schein PS, Banks PM, DeVita VT Jr. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976; 47(1): 3-10. PMID: 1106798.
Kuitunen H, Kaprio E, Karihtala P, Makkonen V, Kauppila S, Haapasaari KM, et al. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. Ann Hematol 2020; 99(8): 1823-1831. doi: 10.1007/s00277-020-04140-0.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329(14): 987-994. doi: 10.1056/NEJM199309303291402.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32(27): 3059-3068. doi: 10.1200/JCO.2013.54.8800.
Morgensztern D, Martin MG, Lossos IS. Gene expression profiling in diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48(4): 669-682. doi: 10.1080/10428190601186176.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503-511. doi: 10.1038/35000501.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25): 1937-1947. doi: 10.1056/NEJMoa012914.
Boltežar L, Prevodnik VK, Perme MP, Gašljević G, Novaković BJ. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett 2018; 15(5): 6903-6912. doi: 10.3892/ol.2018.8243.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275-282. doi: 10.1182/blood-2003-05-1545.
Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26(9): 2103-2113. doi: 10.1038/leu.2012.83.
Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29(2): 200-207. doi: 10.1200/JCO.2010.30.0368.
Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 2009; 22(8): 1094-1101. doi: 10.1038/modpathol.2009.73.
Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117(18): 4836-4843. doi: 10.1182/blood-2010-12-322362.
Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109(11): 4930-4935. doi: 10.1182/blood-2006-09-047068.
de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25(7): 805-812. doi: 10.1200/JCO.2006.09.4490.
Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28(4): 464-470. doi: 10.1097/00000478-200404000-00005.
Lu TX, Miao Y, Wu JZ, Gong QX, Liang JH, Wang Z, et al. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma. Sci Rep 2016; 6: 20465. doi: 10.1038/srep20465.
Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101(1): 78-84. doi: 10.1182/blood-2002-04-1286.
Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, et al, Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier. J Clin Exp Hematop 2017; 57(2): 54-63. doi: 10.3960/jslrt.17029.
Downloads
Published
Versions
- 2023-07-06 (2)
- 2023-06-16 (1)
